Drug Profile
Testosterone undecanoate depot injection - Grunenthal
Alternative Names: Aveed; Nebido; ReandronLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Bayer Schering Pharma
- Developer Bayer HealthCare Pharmaceuticals; Endo Pharmaceuticals Solutions
- Class Anabolic steroids; Androstenols; Hormonal replacements; Small molecules; Testosterone congeners
- Mechanism of Action Testosterone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hypogonadism
Most Recent Events
- 02 Nov 2022 Grunenthal acquires testosterone undecanoate depot injection from Bayer Schering Pharma
- 14 Jul 2022 Bayer has patent protection for testosterone undecanoate depot injection till 2024 in European Union and till 2027 in USA
- 14 Jul 2022 Bayer sells Nebido to Grunenthal for at 500 million Euros